Welcome to our dedicated page for Rogers Corporation news (Ticker: ROG), a resource for investors and traders seeking the latest updates and insights on Rogers Corporation stock.
Rogers Corporation (NYSE: ROG) is a global leader in engineered materials, focusing on enhancing reliability and performance in various industries. With more than 3,000 employees worldwide, Rogers Corporation manufactures its products across 7 countries. The company's primary business segments include Advanced Connectivity Solutions (ACS), Elastomeric Material Solutions (EMS), and Power Electronics Solutions (PES).
The Advanced Connectivity Solutions (ACS) segment produces high-performance circuit materials used in communications infrastructure, automotive, and consumer electronics markets. These materials are essential for enhancing internet connectivity and supporting the rapid growth of communication technologies.
The Elastomeric Material Solutions (EMS) segment offers products designed for cushioning, sealing, and impact protection. These solutions are widely used in the automotive, transportation, and construction industries. EMS products ensure safety and durability, making them indispensable in various applications.
In the Power Electronics Solutions (PES) segment, Rogers Corporation focuses on ceramic substrate materials that are crucial for power module applications. These materials help improve the efficiency and reliability of power electronics, which are vital in clean energy and other technology-driven sectors.
Rogers Corporation's commitment to mission-critical reliability, market-focused innovation, and delivering exceptional value to its customers has positioned it as a trusted partner to many of the world's leading industrial technology providers. The company continually strives to create products that power, protect, and connect our world, driving advancements in clean energy, internet connectivity, and safety.
Rogers Corporation generates significant revenue from key markets in the United States, China, and Germany, while maintaining a global presence that underscores its influence and reach in the industry.
Latest News:
- --- ---
- --- ---
- --- ---
- --- ---
- --- ---
- --- ---
Roche has received CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first immunohistochemistry companion diagnostic test in Europe for identifying epithelial ovarian cancer patients eligible for ELAHERE treatment. The test detects folate receptor 1 protein, expressed in about 90% of ovarian carcinomas. This certification follows an early exemption approval in Germany and Austria earlier this year. The test aims to enable more precise treatment decisions for ovarian cancer, which causes 46,232 deaths annually in Europe and is the eighth leading cause of cancer death in women worldwide.
Rogers (NYSE:ROG) reported mixed Q3 2024 results with net sales of $210.3 million, down 1.8% from Q2. Despite lower sales, earnings exceeded guidance due to operational improvements and expense management. GAAP operating margin improved to 6.9% from 5.3%, while adjusted earnings reached $0.98 per diluted share. The company faced softer EV/HEV demand and lower seasonal peak in portable electronics. Looking ahead, Q4 sales are expected to decline due to seasonality and customer inventory management. The company highlighted its expansion with a new power substrate factory in China targeting EV/HEV, renewable energy, and industrial markets.
Roche has received FDA approval for the VENTANA CLDN18 (43-14A) RxDx Assay, the first companion diagnostic to identify patients with gastric and gastroesophageal junction (GEJ) cancer eligible for targeted treatment with VYLOY. This immunohistochemistry (IHC) assay helps determine CLDN18 protein expression in tumors, enabling clinicians to identify patients who may benefit from Astellas' targeted therapy VYLOY (zolbetuximab).
The assay addresses an unmet medical need by helping predict the likelihood of response to targeted therapy in gastric and GEJ cancers. CLDN18.2 is an emerging biomarker in these cancers. This approval aligns with current guidelines recommending biomarker use to guide therapeutic decision-making in gastric/GEJ cancer.
Gastric cancer is the fifth most common cancer and fourth leading cause of cancer deaths worldwide. In the U.S., 62% of gastric/GEJ cancer cases are advanced at initial diagnosis, with a five-year overall survival rate of only 6%.
Rogers (NYSE:ROG) has announced its plans to release third quarter 2024 financial results on October 24, 2024, after market close. The announcement will be followed by a conference call at 5:00 pm ET, hosted by Colin Gouveia, President and CEO, along with Laura Russell, Interim CFO.
Investors and interested parties can access a live webcast of the event and related slide presentation on Rogers' Investor Relations website. A replay of the event will also be available on the same platform. Rogers is a global leader in engineered materials, specializing in solutions for various industries including automotive, renewable energy, and wireless infrastructure.
Roche's commissioned survey reveals significant gaps in public understanding of HPV and cervical cancer across 12 countries in Latin America and Europe. Key findings include:
- Half of respondents have or no awareness of HPV's role in cervical cancer
- Barriers to screening include fear of pain and discomfort discussing sexual history
- Over 70% of respondents are interested in self-collection options for screening
The survey highlights the need for improved education and accessible screening methods. Roche emphasizes the importance of early detection and prevention, aligning with WHO's goal to eliminate cervical cancer globally. The company has joined the Global HPV Consortium and partners with health systems in over 55 countries to support cervical cancer screening programs using the cobas® HPV test.
Rogers (NYSE: ROG) announced the resignation of CFO Ram Mayampurath, who will remain with the company until September 2024 to ensure a smooth transition. Laura Russell, currently Vice President of Finance, will assume the role of interim CFO effective August 12, 2024. Russell joined Rogers in September 2023 and has previous experience in senior finance roles at Wolfspeed and NXP Semiconductors.
CEO Colin Gouveia expressed gratitude for Mayampurath's contributions over the past 10 years, particularly his efforts in improving profitability and cash flow since becoming CFO in 2021. Rogers has initiated a CFO succession process and will provide updates as appropriate.
Rogers (NYSE:ROG) reported Q2 2024 financial results with net sales of $214.2 million, a 0.4% increase from Q1. GAAP earnings per diluted share were $0.44, up from $0.42 in Q1. Adjusted earnings were $0.69 per diluted share, compared to $0.58 in Q1. The company saw stronger gross margin of 34.1%, up from 32.0% in Q1, driven by favorable product mix and manufacturing cost reductions.
EMS net sales increased by 10.5%, while AES net sales decreased by 5.4%. The company achieved record quarterly sales of EV battery solutions. For Q3 2024, Rogers projects net sales between $215-225 million and adjusted earnings per diluted share of $0.75-$0.95.
Roche (SIX: RO, ROG; OTCQX: RHHBY) will showcase its laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo in Chicago. The company will unveil next-generation core lab and molecular systems, including a total solution for clinical mass spectrometry. Attendees can experience how Roche's integrated systems and data solutions optimize resources and streamline operations.
Key innovations include the future cobas® Mass Spec solution, new CCM Vertical, cobas® liat system for rapid PCR testing, cobas® pure integrated solutions, cobas® eplex system, cobas® 5800, and cobas® LightCycler® PRO. Roche will also present its navify® digital solutions and host Roche Idea Lab sessions featuring industry experts discussing topics such as mass spectrometry, digital solutions, and respiratory testing.
Rogers (NYSE:ROG) has scheduled its second quarter 2024 earnings call for July 25, 2024, following the market close. The call will begin at 5:00 pm ET and will feature presentations by President and CEO Colin Gouveia and CFO Ram Mayampurath. A live webcast and a related slide presentation will be available on Rogers' Investor Relations website, with a replay accessible post-event. Rogers , based in Chandler, Arizona, is a global leader in engineered materials, providing solutions for EV/HEV, automotive safety, radar systems, mobile devices, renewable energy, and more. The company operates manufacturing facilities in the US, Asia, and Europe, and maintains sales offices worldwide.
Rogers (NYSE: ROG) has released its 2024 Environmental, Social, and Governance (ESG) Report. The report showcases Rogers' commitment to sustainability and corporate responsibility, highlighting achievements in reducing energy consumption, greenhouse gas (GHG) emissions, and water usage. Key targets include a 20% reduction in Scope 1 and Scope 2 GHG emissions by 2030. Additionally, the report details Rogers' efforts in employee safety, development, and ethical governance, aligning with recognized sustainability frameworks such as those by the Sustainability Accounting Standards Board. The full report is available on the company's website.
FAQ
What is the current stock price of Rogers Corporation (ROG)?
What is the market cap of Rogers Corporation (ROG)?
What is Rogers Corporation known for?
How many employees does Rogers Corporation have?
In how many countries does Rogers Corporation manufacture its products?
What are the main business segments of Rogers Corporation?
Which markets does Rogers Corporation's ACS segment serve?
What products are offered by the EMS segment of Rogers Corporation?
What does the PES segment of Rogers Corporation focus on?
Where does Rogers Corporation generate significant revenue?
What is the company's approach to innovation?
Who are Rogers Corporation's key partners?
